<?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.2 20190208//EN?>
<?DTDIdentifier.IdentifierType public?>
<?SourceDTD.DTDName JATS-journalpublishing1.dtd?>
<?SourceDTD.Version 1.2?>
<?ConverterInfo.XSLTName jats2jats3.xsl?>
<?ConverterInfo.Version 1?>
<?properties open_access?>
<processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
  <restricted-by>pmc</restricted-by>
</processing-meta>
<front>
  <journal-meta>
    <journal-id journal-id-type="nlm-ta">Nucleic Acids Res</journal-id>
    <journal-id journal-id-type="iso-abbrev">Nucleic Acids Res</journal-id>
    <journal-id journal-id-type="publisher-id">nar</journal-id>
    <journal-title-group>
      <journal-title>Nucleic Acids Research</journal-title>
    </journal-title-group>
    <issn pub-type="ppub">0305-1048</issn>
    <issn pub-type="epub">1362-4962</issn>
    <publisher>
      <publisher-name>Oxford University Press</publisher-name>
    </publisher>
  </journal-meta>
  <article-meta>
    <article-id pub-id-type="pmcid">9825458</article-id>
    <article-id pub-id-type="pmid">36259664</article-id>
    <article-id pub-id-type="doi">10.1093/nar/gkac911</article-id>
    <article-id pub-id-type="publisher-id">gkac911</article-id>
    <article-categories>
      <subj-group subj-group-type="category-taxonomy-collection">
        <subject>AcademicSubjects/SCI00010</subject>
      </subj-group>
      <subj-group subj-group-type="heading">
        <subject>Database Issue</subject>
      </subj-group>
    </article-categories>
    <title-group>
      <article-title>CREAMMIST: an integrative probabilistic database for cancer drug response prediction</article-title>
    </title-group>
    <contrib-group>
      <contrib contrib-type="author" corresp="yes">
        <name>
          <surname>Yingtaweesittikul</surname>
          <given-names>Hatairat</given-names>
        </name>
        <!--hatairat.y@cmu.ac.th-->
        <aff><institution>Advanced Research Center for Computational Simulation, Faculty of Science, Chiang Mai University</institution>, Chiang Mai, <country country="TH">Thailand</country></aff>
        <xref rid="COR2" ref-type="corresp"/>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Wu</surname>
          <given-names>Jiaxi</given-names>
        </name>
        <aff><institution>Genome Institute of Singapore, A*STAR</institution>, Singapore, <country country="SG">Singapore</country></aff>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Mongia</surname>
          <given-names>Aanchal</given-names>
        </name>
        <aff><institution>Genome Institute of Singapore, A*STAR</institution>, Singapore, <country country="SG">Singapore</country></aff>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Peres</surname>
          <given-names>Rafael</given-names>
        </name>
        <aff><institution>Genome Institute of Singapore, A*STAR</institution>, Singapore, <country country="SG">Singapore</country></aff>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Ko</surname>
          <given-names>Karrie</given-names>
        </name>
        <aff><institution>Genome Institute of Singapore, A*STAR</institution>, Singapore, <country country="SG">Singapore</country></aff>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Nagarajan</surname>
          <given-names>Niranjan</given-names>
        </name>
        <aff><institution>Genome Institute of Singapore, A*STAR</institution>, Singapore, <country country="SG">Singapore</country></aff>
      </contrib>
      <contrib contrib-type="author" corresp="yes">
        <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-4777-4586</contrib-id>
        <name>
          <surname>Suphavilai</surname>
          <given-names>Chayaporn</given-names>
        </name>
        <!--suphavilaic@gis.a-star.edu.sg-->
        <aff><institution>Genome Institute of Singapore, A*STAR</institution>, Singapore, <country country="SG">Singapore</country></aff>
        <xref rid="COR1" ref-type="corresp"/>
      </contrib>
    </contrib-group>
    <author-notes>
      <corresp id="COR1">To whom correspondence should be addressed. Tel: +65 86213683; Fax: +65 68088292; Email: <email>suphavilaic@gis.a-star.edu.sg</email></corresp>
      <corresp id="COR2">Correspondence may also be addressed to Hatairat Yingtaweesittikul. Email: <email>hatairat.y@cmu.ac.th</email></corresp>
    </author-notes>
    <pub-date pub-type="collection">
      <day>06</day>
      <month>1</month>
      <year>2023</year>
    </pub-date>
    <pub-date pub-type="epub" iso-8601-date="2022-10-19">
      <day>19</day>
      <month>10</month>
      <year>2022</year>
    </pub-date>
    <pub-date pub-type="pmc-release">
      <day>19</day>
      <month>10</month>
      <year>2022</year>
    </pub-date>
    <volume>51</volume>
    <issue>D1</issue>
    <fpage>D1242</fpage>
    <lpage>D1248</lpage>
    <history>
      <date date-type="accepted">
        <day>11</day>
        <month>10</month>
        <year>2022</year>
      </date>
      <date date-type="rev-recd">
        <day>18</day>
        <month>9</month>
        <year>2022</year>
      </date>
      <date date-type="received">
        <day>14</day>
        <month>8</month>
        <year>2022</year>
      </date>
    </history>
    <permissions>
      <copyright-statement>© The Author(s) 2022. Published by Oxford University Press on behalf of Nucleic Acids Research.</copyright-statement>
      <copyright-year>2023</copyright-year>
      <license>
        <ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
        <license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p>
      </license>
    </permissions>
    <self-uri xlink:href="gkac911.pdf"/>
    <abstract>
      <title>Abstract</title>
      <p>Extensive <italic toggle="yes">in vitro</italic> cancer drug screening datasets have enabled scientists to identify biomarkers and develop machine learning models for predicting drug sensitivity. While most advancements have focused on omics profiles, cancer drug sensitivity scores precalculated by the original sources are often used as-is, without consideration for variabilities between studies. It is well-known that significant inconsistencies exist between the drug sensitivity scores across datasets due to differences in experimental setups and preprocessing methods used to obtain the sensitivity scores. As a result, many studies opt to focus only on a single dataset, leading to underutilization of available data and a limited interpretation of cancer pharmacogenomics analysis. To overcome these caveats, we have developed CREAMMIST (<ext-link xlink:href="https://creammist.mtms.dev" ext-link-type="uri">https://creammist.mtms.dev</ext-link>), an integrative database that enables users to obtain an integrative dose-response curve, to capture uncertainty (or high certainty when multiple datasets well align) across five widely used cancer cell-line drug–response datasets. We utilized the Bayesian framework to systematically integrate all available dose-response values across datasets (&gt;14 millions dose-response data points). CREAMMIST provides easy-to-use statistics derived from the integrative dose-response curves for various downstream analyses such as identifying biomarkers, selecting drug concentrations for experiments, and training robust machine learning models.</p>
    </abstract>
    <abstract abstract-type="graphical">
      <title>Graphical Abstract</title>
      <p>
        <fig position="float" id="ga1">
          <label>Graphical Abstract</label>
          <caption>
            <p>CREAMMIST is an integrative probabilistic database for cancer drug response prediction and pharmacogenomics analysis. It combines widely used in vitro cancer drug screening datasets and provides integrative dose-response curves.</p>
          </caption>
          <graphic xlink:href="gkac911figgra1" position="float"/>
        </fig>
      </p>
    </abstract>
    <funding-group>
      <award-group award-type="grant">
        <funding-source>
          <institution-wrap>
            <institution>Chiang Mai University</institution>
            <institution-id institution-id-type="DOI">10.13039/501100002842</institution-id>
          </institution-wrap>
        </funding-source>
      </award-group>
      <award-group award-type="grant">
        <funding-source>
          <institution-wrap>
            <institution>A*STAR</institution>
            <institution-id institution-id-type="DOI">10.13039/501100001348</institution-id>
          </institution-wrap>
        </funding-source>
      </award-group>
      <award-group award-type="grant">
        <funding-source>
          <institution-wrap>
            <institution>National Medical Research Council</institution>
            <institution-id institution-id-type="DOI">10.13039/501100001349</institution-id>
          </institution-wrap>
        </funding-source>
      </award-group>
      <award-group award-type="grant">
        <funding-source>
          <institution-wrap>
            <institution>Genome Institute of Singapore</institution>
            <institution-id institution-id-type="DOI">10.13039/501100005606</institution-id>
          </institution-wrap>
        </funding-source>
      </award-group>
    </funding-group>
    <counts>
      <page-count count="7"/>
    </counts>
  </article-meta>
</front>
<body>
  <sec sec-type="intro" id="SEC1">
    <title>INTRODUCTION</title>
    <p>Cancer is a complex disease in which inter- and intra-tumor heterogeneity can impact treatment and clinical outcomes (<xref rid="B1" ref-type="bibr">1–5</xref>). High-throughput multi-omics and pharmacological profiling of cancer cell lines have been instrumental in characterizing molecular features which may aid drug–response predictions (<xref rid="B4" ref-type="bibr">4–6</xref>). Pioneer large screening cancer drug response datasets such as CCLE (<xref rid="B7" ref-type="bibr">7</xref>) and GDSC (<xref rid="B8" ref-type="bibr">8</xref>) have enabled scientists to gain more insight into pharmacogenomics via computational techniques for biomarker discovery and machine learning models for drug response predictions.</p>
    <p>In recent years, several biomarkers were computationally identified based on the information from the large-scale cancer drug screening on hundreds of cancer cell lines (<xref rid="B11" ref-type="bibr">11–13</xref>). Due to the complexity of drug response mechanisms (<xref rid="B14" ref-type="bibr">14</xref>,<xref rid="B15" ref-type="bibr">15</xref>), various machine learning techniques have been used for predicting drug response based on omics profiles (<xref rid="B16" ref-type="bibr">16–20</xref>). Increasingly complex analysis techniques such as multimodal learning (<xref rid="B21" ref-type="bibr">21–23</xref>), visible machine learning (<xref rid="B24" ref-type="bibr">24</xref>), domain adaptation (<xref rid="B25" ref-type="bibr">25–27</xref>), and graph representation (<xref rid="B28" ref-type="bibr">28–30</xref>) have been explored. While most advancements in biomarker identification and machine learning models have focused on omics profiles, cancer drug sensitivity scores precalculated by the original sources are often used as-is, without consideration for variabilities between studies.</p>
    <p>Commonly used scores include IC<sub>50</sub> (a drug concentration that inhibits 50% of the cancer cells) or AUC (an area under the dose-response curve) values, which are inferred from multiple dose-response data points. Due to differences in experimental setups and preprocessing methods used to obtain the sensitivity scores, it is well-known that significant inconsistencies exist between the sensitivity scores across datasets (<xref rid="B31" ref-type="bibr">31–34</xref>). As a result, many studies opt to focus only on a single dataset, leading to the under-utilization of available data and a limited interpretation of cancer pharmacogenomics analysis.</p>
    <p>Existing studies have attempted to mitigate the inconsistency using different strategies such as discretizing drug sensitivity levels (<xref rid="B35" ref-type="bibr">35</xref>,<xref rid="B36" ref-type="bibr">36</xref>), considering shared drug concentration ranges across multiple datasets (<xref rid="B37" ref-type="bibr">37</xref>), or investigating genetic and transcriptional evolutions that alter drug response in cancer cell lines (<xref rid="B38" ref-type="bibr">38</xref>). A few existing tools, such as PharmacoDB (<xref rid="B39" ref-type="bibr">39</xref>) and CellMinerCBD (<xref rid="B40" ref-type="bibr">40</xref>), have integrated multiple datasets and standardized the preprocessing methods for dose-response curves. However, the dose-response curve was processed separately for each dataset. Additionally, because an integrative summary of the dose-response curve across datasets was not provided, the variations (or uncertainties) of sensitivity scores at a specific drug dosage could not be captured.</p>
    <p>To overcome these caveats, we have developed CREAMMIST, an integrative database that enables users to obtain an integrative dose-response, capturing uncertainty (or high certainty when multiple datasets are well aligned) across five widely used cancer cell-line drug–response datasets. Instead of estimating a dose-response curve for each dataset separately, we utilized the Bayesian framework to systematically integrate all available dose-response data points across datasets. The integration at the dose-response level provides an extended view of the dose-response curve to users, especially when different ranges of drug dosages were used across experiments.</p>
    <p>We envision that CREAMMIST would suit various user types. Users can utilize easy-to-use statistics derived from the integrative dose-response curves for various downstream analyses such as identifying biomarkers, selecting drug concentrations for their experiments, and training robust machine learning models. An ability to visualize and extract the variations of the drug response across multiple datasets allows users to anticipate variability at various dosages and formulate their experiments accordingly.</p>
  </sec>
  <sec sec-type="materials|methods" id="SEC2">
    <title>MATERIALS AND METHODS</title>
    <sec id="SEC2-1">
      <title>Data collection and processing</title>
      <p>Raw dose-response and omic profiles were downloaded and standardized for data downstream integrative analysis (Figure <xref rid="F1" ref-type="fig">1A</xref>). Raw dose-response data and precalculated IC<sub>50</sub> and AUC values were downloaded from CCLE (<xref rid="B9" ref-type="bibr">9</xref>), GDSC (<xref rid="B10" ref-type="bibr">10</xref>) and CTRP (<xref rid="B41" ref-type="bibr">41</xref>). Gene expression and mutation data were downloaded from Cell Model Passport (<xref rid="B42" ref-type="bibr">42</xref>). For gene expression, we used TPM normalized values. For mutation, non-silent mutations in coding regions with allele frequency of at least 0.2 were selected for analysis. All cell line names were standardized based on Cellosaurus database (<xref rid="B43" ref-type="bibr">43</xref>), and drug names were manually curated by considering drug synonyms.</p>
      <fig position="float" id="F1">
        <label>Figure 1.</label>
        <caption>
          <p>Flow chart of CREAMMIST. (<bold>A</bold>) Data collection and processing. Raw dose-response information, gene expression, and mutation profile are downloaded from CCLE, GDSC, and CTRP datasets. Cell line and drug names are standardized. Raw dose-response values are normalized and integrated into the database. (<bold>B</bold>) Bayesian curve fitting for an integrative dose-response curve. Multiple drug response statistics are calculated for each drug-cell line pair. (<bold>C</bold>) Quantifying the effect size of mutation on drug response (IC<sub>50</sub> values) and calculating the correlation between gene expression level and drug response (IC<sub>50</sub> values). (<bold>D</bold>) Storage and infrastructure of CREAMMIST.</p>
        </caption>
        <graphic xlink:href="gkac911fig1" position="float"/>
      </fig>
      <p>For each dataset, drug concentration is in <inline-formula><tex-math id="M0001" notation="LaTeX">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
}{}$\mu$\end{document}</tex-math></inline-formula>M unit, and response values at different concentrations were standardized in the range of 0 to 1 with respect to positive and negative control wells (<xref rid="sup1" ref-type="supplementary-material">Supplementary Figure S1</xref>), where 0 indicates no response (i.e. the same response level as negative control) and 1 indicates complete inhibition (i.e. the same response level as positive control). In total, CREAMMIST contains 1325 cell lines from 31 cancer types, 1132 drugs, 829 782 pairs of cell lines and drugs, and 14 174 707 dose-response data points (<xref rid="sup1" ref-type="supplementary-material">Supplementary Figure S2</xref>).</p>
    </sec>
    <sec id="SEC2-2">
      <title>Database organization</title>
      <p>We used a relational database as a backend data storage to maintain both drug response and genotype information, as well as cell lines, drugs, and genes information. The database schema was designed to support multiple query types and identify candidate biomarkers using the original drug response score or the newly calculated drug response score based on the integrative dose-response curves (<xref rid="sup1" ref-type="supplementary-material">Supplementary Figure S3</xref>).</p>
    </sec>
    <sec id="SEC2-3">
      <title>Integration of dose–response data</title>
      <p>To obtain an integrative dose–response curve across datasets for each pair of drug and cell line, we applied Bayesian curve fitting by using PyJags v1.3.7 (<xref rid="B44" ref-type="bibr">44</xref>) for the inference (Figure <xref rid="F1" ref-type="fig">1B</xref>). A commonly used logistic equation is defined as <inline-formula><tex-math id="M0001a" notation="LaTeX">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
}{}$f( x ) = \frac{1}{{1 + {2}^{ - k( {x - a} )}}}$\end{document}</tex-math></inline-formula>, where <inline-formula><tex-math id="M0002" notation="LaTeX">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
}{}$x$\end{document}</tex-math></inline-formula> represents drug concentration, <inline-formula><tex-math id="M0003" notation="LaTeX">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
}{}$a$\end{document}</tex-math></inline-formula> represents the center position of the dose-response curve, and <inline-formula><tex-math id="M0004" notation="LaTeX">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
}{}$k$\end{document}</tex-math></inline-formula> is the slope of the dose–response curve.</p>
      <p>For the inference, we conducted three chains, where we performed 5000 iterations for each chain with 500 burn-in iterations. Different types of distributions were used for each parameter as follows. For robust estimation of the response value <inline-formula><tex-math id="M0005" notation="LaTeX">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
}{}$f( x )$\end{document}</tex-math></inline-formula>, we used a student's t-distribution <inline-formula><tex-math id="M0006" notation="LaTeX">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
}{}$dt( {\frac{1}{{1 + {2}^{ - k( {x - a} )}}},\ {{( {\frac{1}{\sigma }} )}}^2,\ \nu } )$\end{document}</tex-math></inline-formula> with <inline-formula><tex-math id="M0007" notation="LaTeX">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
}{}$\nu \sim dnorm( {250,\ 0.001} )$\end{document}</tex-math></inline-formula> and <inline-formula><tex-math id="M0008" notation="LaTeX">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
}{}$\sigma \sim dunif( {0.01,\ 0.1} )$\end{document}</tex-math></inline-formula> as priors. The center position <inline-formula><tex-math id="M0009" notation="LaTeX">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
}{}$a$\end{document}</tex-math></inline-formula> that represents IC<sub>50</sub> was estimated using a normal distribution <inline-formula><tex-math id="M00010" notation="LaTeX">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
}{}$a \sim dnorm( {{a}_\mu ,\ {{( {\frac{1}{{{a}_\sigma }}} )}}^2} )$\end{document}</tex-math></inline-formula> with <inline-formula><tex-math id="M00011" notation="LaTeX">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
}{}${a}_\mu \sim dnorm( {0,\ 1} )$\end{document}</tex-math></inline-formula> and <inline-formula><tex-math id="M00012" notation="LaTeX">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
}{}${a}_\sigma \sim dunif( {0.01, 5} )$\end{document}</tex-math></inline-formula> as priors. A non-negative slope value was estimated using a gamma distribution, <inline-formula><tex-math id="M00013" notation="LaTeX">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
}{}$k \sim dgamma( {{k}_r,\ {k}_\lambda } )$\end{document}</tex-math></inline-formula> with <inline-formula><tex-math id="M00014" notation="LaTeX">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
}{}${k}_\lambda \sim dnorm( {2,\ 0.01} )$\end{document}</tex-math></inline-formula> and <inline-formula><tex-math id="M00015" notation="LaTeX">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
}{}${k}_r \sim dnorm( {1,\ 0.01} )$\end{document}</tex-math></inline-formula> as priors.</p>
      <p>Multiple statistics, including mode and high-density interval (95% HDI) of parameters <inline-formula><tex-math id="M00016" notation="LaTeX">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
}{}$a$\end{document}</tex-math></inline-formula> and <inline-formula><tex-math id="M00017" notation="LaTeX">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
}{}$k$\end{document}</tex-math></inline-formula>, as well as mean absolute error of the fitting, were obtained from the Bayesian fitted curves using Arviz v0.11.4, a Python package for exploratory analysis of Bayesian models (<xref rid="B45" ref-type="bibr">45</xref>). In addition to IC<sub>50</sub>, which corresponds to the center position of the curve, CREAMMIST also provides a drug concentration required for 90% inhibition of cell growth (IC<sub>90</sub>), area under the dose-response curve (AUC), a drug concentration at which 50% of its maximal response is induced (EC<sub>50</sub>), and maximum response caused by a drug (E<sub>inf</sub>).</p>
    </sec>
    <sec id="SEC2-4">
      <title>Identifying biomarkers from integrative dose-response information</title>
      <p>To provide an overview of relationships between drug and gene, we compared IC<sub>50</sub> obtained from the integrative curve against mutation and gene expression information of all (or cancer type specific) cell lines tested for each drug (Figure <xref rid="F1" ref-type="fig">1C</xref>). The mutational effect of each gene on drug response was calculated by using the Wilcoxon rank-sum test to compare IC<sub>50</sub> values between wild-type and mutant cell lines. Wilcoxon rank-sum test was only performed for drug–gene pairs with at least ten wild-type and 10 mutant cell lines. The effect of gene expression level on drug response was calculated using Spearman correlation to avoid the extreme correlation value for some drug–gene pairs with outliers. Similar to the mutation data, the correlation was only calculated for drug–gene pairs with at least ten cell lines. To avoid the correlation calculation for noisy background gene expression values, we also required that at least five cell lines have at least one transcript per million (TPM).</p>
    </sec>
    <sec id="SEC2-5">
      <title>Implementation and web interface</title>
      <p>All standardized dose-response data, integrative dose-response curves, omics profiles, and biomarkers information were stored in MySQL v8.0.30 (Figure <xref rid="F1" ref-type="fig">1D</xref>). CREAMMIST web application was deployed using Gunicorn v20.1.0, a Python Web Server Gateway Interface <ext-link xlink:href="http://HTTP" ext-link-type="uri">HTTP</ext-link> server. We used Nginx v1.18.0 as a proxy server and secured the connection with Let's Encrypt via certbot v0.40.0.</p>
      <p>We used Flask v2.0.3 as a web application framework to implement CREAMMIST modules, including Cell lines, Drugs, Cancer types, Genes, and Biomarkers. We also utilized extensions such as Flask-Migrate v3.1.0 for database migration, Jinja2 v3.0.3 for HTML template management, and jQuery v1.12.1 for keyword suggestion. To enable a fully responsive web interface for both mobile and desktop users, we used Bootstrap v5.1.3. In addition to accessing the database via the web interface, we provide an Application Programming Interface (API), which allows other applications to access CREAMMIST.</p>
    </sec>
  </sec>
  <sec id="SEC3">
    <title>DATABASE CONTENT AND USAGE</title>
    <sec id="SEC3-1">
      <title>Integrative dose-response curve</title>
      <p>The key component of CREAMMIST is the integrative dose–response curve using Bayesian curve fitting. Fitting the dose–response curve independently for each dataset might lead to inconsistency of IC<sub>50</sub> values. For instance, when the predetermined drug concentration range is on the lower end, we might not observe the inhibition effect and, consequently, IC<sub>50</sub> is either not defined or too high because of the extrapolation. In contrast, the integrative dose–response curve consists of standardized dose–response data points from all available datasets for a given drug-cell line pair (Figure <xref rid="F2" ref-type="fig">2</xref>). Fitting a curve based on all dose–response data points allows users to view the response at a broader drug concentration range (Figure <xref rid="F2" ref-type="fig">2A</xref>). Moreover, using probabilistic curve fitting allows users to inspect the uncertainty at different drug concentrations (Figure <xref rid="F2" ref-type="fig">2B</xref>, grey lines) and capture the common trend in the presence of discordance between datasets (Figure <xref rid="F2" ref-type="fig">2C</xref>).</p>
      <fig position="float" id="F2">
        <label>Figure 2.</label>
        <caption>
          <p>Integrative dose-response curves, where x-axis represents drug concentration and y-axis represents drug response level compared to the respective controls. Each color represents a dataset. Grey lines represent multiple curves resulting from Bayesian curve fitting, and a pink line represents the integrative dose–response curve based on mode values, i.e. location and slope parameters of a logistic function. Integrative dose–response curves capture (<bold>A</bold>) broaden concentration range by combining all dose-response data points across multiple datasets (<bold>B</bold>) uncertainty at different concentration levels (<bold>C</bold>) common trends across multiple datasets in the presence of discordance between datasets.</p>
        </caption>
        <graphic xlink:href="gkac911fig2" position="float"/>
      </fig>
      <p>Although CREAMMIST allows comprehensive views of drug response across multiple datasets, there are some limitations of the integrative dose-response curves obtained from Bayesian curve fitting. As the fitted dose-response curves start at 0 (no response) and rise to 1 (complete inhibition), for highly resistant cases, drug sensitivity scores such as IC<sub>50</sub> can be relatively high because the scores rely on extrapolation. In addition, the inferred curves might not well capture actual response values for a few outlier cases. Therefore, depending on the studies’ aims, users may consider high-density intervals of the sensitivity scores or mean absolute errors of the fitted curves to select drug-cell line pairs for their analysis.</p>
    </sec>
    <sec id="SEC3-2">
      <title>User interface modules</title>
      <p>The front page of CREAMMIST explains the concept of the integrative dose-response curve and allows users to browse through the database from different perspectives (Figure <xref rid="F3" ref-type="fig">3</xref>). CREAMMIST provides interactive plots for users to view the integrative dose-response curve, IC<sub>50</sub> distribution inferred from the Bayesian curve fitting, and five drug sensitivity scores based on the integrative dose-response curve (Figure <xref rid="F3" ref-type="fig">3A</xref>). Users can select the following modules to start searching or browsing. Information on every webpage is downloadable in a text format, and plots are downloadable in SVG format.</p>
      <fig position="float" id="F3">
        <label>Figure 3.</label>
        <caption>
          <p>Overview of CREAMMIST web interface. (<bold>A</bold>) Interactive visualization of the integrative dose-response curve for a given drug-cell line pair. Based on the Bayesian curve fitting results, CREAMMIST provides IC<sub>50</sub> distribution and multiple drug sensitivity scores. (<bold>B</bold>) Cell line module provides cell line information and relevant drug screening experiment information. (<bold>C</bold>) Cancer type module provides overall information across all cell lines belonging to a given cancer type. (<bold>D</bold>) Drug module provides drug information and relevant drug screening experiment information. (<bold>E</bold>) Biomarker module contains drug–gene associations based on mutation and gene expression. (<bold>F</bold>) Gene module provides gene information and relevant drug–gene associations.</p>
        </caption>
        <graphic xlink:href="gkac911fig3" position="float"/>
      </fig>
    </sec>
    <sec id="SEC3-3">
      <title>Cell line module</title>
      <p>Users search or browse the database by cell line name. The cell line page shows cell line information alongside relevant drug screening experiments and top drugs based on various sensitivity scores (Figure <xref rid="F3" ref-type="fig">3B</xref>). For each experiment, users can extract more detail and visualize the integrative dose-response curve.</p>
    </sec>
    <sec id="SEC3-4">
      <title>Cancer type module</title>
      <p>To study cancer-specific drug response, users can select the cancer type of interest to retrieve drug response information. Users can also select to view either the sensitivity scores based on the integrative dose-response curve or the provided scores from the original data sources (Figure <xref rid="F3" ref-type="fig">3C</xref>).</p>
    </sec>
    <sec id="SEC3-5">
      <title>Drug module</title>
      <p>Users search or browse the database by drug name. The drug page shows drug information alongside relevant drug screening experiments and top cell lines based on various sensitivity scores (Figure <xref rid="F3" ref-type="fig">3D</xref>). Similar to the cell line module, users can extract more detail and visualize the integrative dose-response curve.</p>
    </sec>
    <sec id="SEC3-6">
      <title>Biomarker module</title>
      <p>CREMMIST precalculated the effect of genetic alteration, including point mutations and changes in gene expression level, on each drug. Users can search a gene-drug pair to view the details, and the interactive plots allow users to inspect the values of each data point (Figure <xref rid="F3" ref-type="fig">3E</xref>). Users can also select cancer types to extract the effects calculated based only on cell lines from a given cancer type.</p>
    </sec>
    <sec id="SEC3-7">
      <title>Gene module</title>
      <p>Users search or browse the database by gene name. The gene page shows gene information alongside relevant drugs based on the effect scores (Figure <xref rid="F3" ref-type="fig">3F</xref>). For each drug, users can extract more detail and inspect the gene–drug relationships through the Biomarker module.</p>
    </sec>
  </sec>
  <sec id="SEC4">
    <title>SUMMARY AND FUTURE DIRECTIONS</title>
    <p>We systematically integrated dose-response data from multiple data sources, allowing users to retrieve the integrative dose-response curves. CREAMMIST provides easy-to-use statistics, interactive plots, and API for programmatically accessing the database consisting of more than 14 millions dose-response data points. Instead of attempting to remove the unavoidable inconsistency between studies or even among replicates, we applied a Bayesian framework for dose-response curve fitting to capture the uncertainties at different drug concentration levels. Users can obtain drug response information from broader drug concentration ranges and, at the same time, be able to anticipate variability at various dosages and formulate their experiments accordingly.</p>
    <p>CREAMMIST can be useful for various downstream analyses such as identifying biomarkers, selecting drug concentrations for future experiments, and training a more robust machine learning model by incorporating confidence interval information. Going forwards, CREMMIST can be enhanced by: (a) incorporating chemical properties of the drugs, enabling users to search for similar drugs based on both response profiles and chemical similarity; (b) applying matrix factorization, a technique used in recommender systems, to facilitate users to discover similar drugs (or cell lines or genes); (c) taking into account additional experimental setup information such as durations and different types of controls for more advance search and analysis; (d) integrating other types of omics profiles; and (e) allowing users to incorporate their in-house experimental results such as drug screening on patient-derived cell lines.</p>
    <p>Despite advances in the pharmacogenomic field and sequencing technologies, less than a quarter of oncology patients benefit directly from precision medicine (<xref rid="B46" ref-type="bibr">46</xref>,<xref rid="B47" ref-type="bibr">47</xref>). Most treatments still rely on invasive, toxic standard therapies because physicians had no way to reliably predict which drug would work best for each patient (<xref rid="B48" ref-type="bibr">48</xref>). Diverse strategies to make use of the existing cancer drug screening data are needed not only for biomarker identification but also for building knowledge to guide drug repropositioning (<xref rid="B11" ref-type="bibr">11</xref>,<xref rid="B49" ref-type="bibr">49</xref>). As inter- and intra-tumor heterogeneity pose further challenges to cancer treatments, the diversity of cancer cell lines with drug response information could also reveal distinct drug response behaviors across subpopulations (<xref rid="B50" ref-type="bibr">50</xref>,<xref rid="B51" ref-type="bibr">51</xref>) as well as novel target populations (<xref rid="B52" ref-type="bibr">52</xref>).</p>
  </sec>
  <sec sec-type="supplementary-material">
    <title>Supplementary Material</title>
    <supplementary-material id="sup1" position="float" content-type="local-data">
      <label>gkac911_Supplemental_File</label>
      <media xlink:href="gkac911_supplemental_file.pdf">
        <caption>
          <p>Click here for additional data file.</p>
        </caption>
      </media>
    </supplementary-material>
  </sec>
</body>
<back>
  <ack id="ACK1">
    <title>ACKNOWLEDGEMENTS</title>
    <p>We thank the members of the Laboratory of Metagenomics Technologies and Microbial Systems for their help with web testing.</p>
  </ack>
  <sec id="SEC5">
    <title>SUPPLEMENTARY DATA</title>
    <p><ext-link xlink:href="https://academic.oup.com/nar/article-lookup/doi/10.1093/nar/gkac911#supplementary-data" ext-link-type="uri">Supplementary Data</ext-link> are available at NAR Online.</p>
  </sec>
  <sec id="SEC6">
    <title>FUNDING</title>
    <p>Chiang Mai University and A*STAR; K.K. was supported by the Singapore National Medical Research Council research training fellowship. Funding for open access charge: Genome Institute of Singapore, A*STAR Research Entities.</p>
    <p><italic toggle="yes">Conflict of interest statement</italic>. None declared.</p>
  </sec>
  <notes id="NT1">
    <title>Notes</title>
    <p>Present address: Chayaporn Suphavilai, Genome Institute of Singapore, A*STAR Research Institute, 60 Biopolis Way, 138672 Singapore.</p>
  </notes>
  <ref-list id="REF1">
    <title>REFERENCES</title>
    <ref id="B1">
      <label>1.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Hanahan</surname><given-names>D.</given-names></string-name>, <string-name><surname>Weinberg</surname><given-names>R.A.</given-names></string-name></person-group><article-title>The hallmarks of cancer</article-title>. <source>Cell</source>. <year>2000</year>; <volume>100</volume>:<fpage>57</fpage>–<lpage>70</lpage>.<pub-id pub-id-type="pmid">10647931</pub-id></mixed-citation>
    </ref>
    <ref id="B2">
      <label>2.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Hanahan</surname><given-names>D.</given-names></string-name>, <string-name><surname>Weinberg</surname><given-names>R.A.</given-names></string-name></person-group><article-title>Hallmarks of cancer: the next generation</article-title>. <source>Cell</source>. <year>2011</year>; <volume>144</volume>:<fpage>646</fpage>–<lpage>674</lpage>.<pub-id pub-id-type="pmid">21376230</pub-id></mixed-citation>
    </ref>
    <ref id="B3">
      <label>3.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Hanahan</surname><given-names>D.</given-names></string-name></person-group><article-title>Hallmarks of cancer: new dimensions</article-title>. <source>Cancer Discov.</source><year>2022</year>; <volume>12</volume>:<fpage>31</fpage>–<lpage>46</lpage>.<pub-id pub-id-type="pmid">35022204</pub-id></mixed-citation>
    </ref>
    <ref id="B4">
      <label>4.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Sun</surname><given-names>X.-X.</given-names></string-name>, <string-name><surname>Yu</surname><given-names>Q.</given-names></string-name></person-group><article-title>Intra-tumor heterogeneity of cancer cells and its implications for cancer treatment</article-title>. <source>Acta Pharmacol. Sin.</source><year>2015</year>; <volume>36</volume>:<fpage>1219</fpage>–<lpage>1227</lpage>.<pub-id pub-id-type="pmid">26388155</pub-id></mixed-citation>
    </ref>
    <ref id="B5">
      <label>5.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Turner</surname><given-names>N.C.</given-names></string-name>, <string-name><surname>Reis-Filho</surname><given-names>J.S.</given-names></string-name></person-group><article-title>Genetic heterogeneity and cancer drug resistance</article-title>. <source>Lancet Oncol.</source><year>2012</year>; <volume>13</volume>:<fpage>e178</fpage>–<lpage>e185</lpage>.<pub-id pub-id-type="pmid">22469128</pub-id></mixed-citation>
    </ref>
    <ref id="B6">
      <label>6.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Goodspeed</surname><given-names>A.</given-names></string-name>, <string-name><surname>Heiser</surname><given-names>L.M.</given-names></string-name>, <string-name><surname>Gray</surname><given-names>J.W.</given-names></string-name>, <string-name><surname>Costello</surname><given-names>J.C.</given-names></string-name></person-group><article-title>Tumor-Derived cell lines as molecular models of cancer pharmacogenomics</article-title>. <source>Mol. Cancer Res.</source><year>2016</year>; <volume>14</volume>:<fpage>3</fpage>–<lpage>13</lpage>.<pub-id pub-id-type="pmid">26248648</pub-id></mixed-citation>
    </ref>
    <ref id="B7">
      <label>7.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Barretina</surname><given-names>J.</given-names></string-name>, <string-name><surname>Caponigro</surname><given-names>G.</given-names></string-name>, <string-name><surname>Stransky</surname><given-names>N.</given-names></string-name>, <string-name><surname>Venkatesan</surname><given-names>K.</given-names></string-name>, <string-name><surname>Margolin</surname><given-names>A.A.</given-names></string-name>, <string-name><surname>Kim</surname><given-names>S.</given-names></string-name>, <string-name><surname>Wilson</surname><given-names>C.J.</given-names></string-name>, <string-name><surname>Lehár</surname><given-names>J.</given-names></string-name>, <string-name><surname>Kryukov</surname><given-names>G.V.</given-names></string-name>, <string-name><surname>Sonkin</surname><given-names>D.</given-names></string-name><etal>et al</etal>.</person-group><article-title>The cancer cell line encyclopedia enables predictive modelling of anticancer drug sensitivity</article-title>. <source>Nature</source>. <year>2012</year>; <volume>483</volume>:<fpage>603</fpage>–<lpage>607</lpage>.<pub-id pub-id-type="pmid">22460905</pub-id></mixed-citation>
    </ref>
    <ref id="B8">
      <label>8.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Lavertu</surname><given-names>A.</given-names></string-name>, <string-name><surname>McInnes</surname><given-names>G.</given-names></string-name>, <string-name><surname>Daneshjou</surname><given-names>R.</given-names></string-name>, <string-name><surname>Whirl-Carrillo</surname><given-names>M.</given-names></string-name>, <string-name><surname>Klein</surname><given-names>T.E.</given-names></string-name>, <string-name><surname>Altman</surname><given-names>R.B.</given-names></string-name></person-group><article-title>Pharmacogenomics and big genomic data: from lab to clinic and back again</article-title>. <source>Hum. Mol. Genet.</source><year>2018</year>; <volume>27</volume>:<fpage>R72</fpage>–<lpage>R78</lpage>.<pub-id pub-id-type="pmid">29635477</pub-id></mixed-citation>
    </ref>
    <ref id="B9">
      <label>9.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Ghandi</surname><given-names>M.</given-names></string-name>, <string-name><surname>Huang</surname><given-names>F.W.</given-names></string-name>, <string-name><surname>Jané-Valbuena</surname><given-names>J.</given-names></string-name>, <string-name><surname>Kryukov</surname><given-names>G.V.</given-names></string-name>, <string-name><surname>Lo</surname><given-names>C.C.</given-names></string-name>, <string-name><surname>McDonald</surname><given-names>E.R.</given-names></string-name>, <string-name><surname>Barretina</surname><given-names>J.</given-names></string-name>, <string-name><surname>Gelfand</surname><given-names>E.T.</given-names></string-name>, <string-name><surname>Bielski</surname><given-names>C.M.</given-names></string-name>, <string-name><surname>Li</surname><given-names>H.</given-names></string-name><etal>et al</etal>.</person-group><article-title>Next-generation characterization of the cancer cell line encyclopedia</article-title>. <source>Nature</source>. <year>2019</year>; <volume>569</volume>:<fpage>503</fpage>–<lpage>508</lpage>.<pub-id pub-id-type="pmid">31068700</pub-id></mixed-citation>
    </ref>
    <ref id="B10">
      <label>10.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Iorio</surname><given-names>F.</given-names></string-name>, <string-name><surname>Knijnenburg</surname><given-names>T.A.</given-names></string-name>, <string-name><surname>Vis</surname><given-names>D.J.</given-names></string-name>, <string-name><surname>Bignell</surname><given-names>G.R.</given-names></string-name>, <string-name><surname>Menden</surname><given-names>M.P.</given-names></string-name>, <string-name><surname>Schubert</surname><given-names>M.</given-names></string-name>, <string-name><surname>Aben</surname><given-names>N.</given-names></string-name>, <string-name><surname>Gonçalves</surname><given-names>E.</given-names></string-name>, <string-name><surname>Barthorpe</surname><given-names>S.</given-names></string-name>, <string-name><surname>Lightfoot</surname><given-names>H.</given-names></string-name><etal>et al</etal>.</person-group><article-title>A landscape of pharmacogenomic interactions in cancer</article-title>. <source>Cell</source>. <year>2016</year>; <volume>166</volume>:<fpage>740</fpage>–<lpage>754</lpage>.<pub-id pub-id-type="pmid">27397505</pub-id></mixed-citation>
    </ref>
    <ref id="B11">
      <label>11.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Tanoli</surname><given-names>Z.</given-names></string-name>, <string-name><surname>Seemab</surname><given-names>U.</given-names></string-name>, <string-name><surname>Scherer</surname><given-names>A.</given-names></string-name>, <string-name><surname>Wennerberg</surname><given-names>K.</given-names></string-name>, <string-name><surname>Tang</surname><given-names>J.</given-names></string-name>, <string-name><surname>Vähä-Koskela</surname><given-names>M.</given-names></string-name></person-group><article-title>Exploration of databases and methods supporting drug repurposing: a comprehensive survey</article-title>. <source>Brief. Bioinform.</source><year>2021</year>; <volume>22</volume>:<fpage>1656</fpage>–<lpage>1678</lpage>.<pub-id pub-id-type="pmid">32055842</pub-id></mixed-citation>
    </ref>
    <ref id="B12">
      <label>12.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Cokelaer</surname><given-names>T.</given-names></string-name>, <string-name><surname>Chen</surname><given-names>E.</given-names></string-name>, <string-name><surname>Iorio</surname><given-names>F.</given-names></string-name>, <string-name><surname>Menden</surname><given-names>M.P.</given-names></string-name>, <string-name><surname>Lightfoot</surname><given-names>H.</given-names></string-name>, <string-name><surname>Saez-Rodriguez</surname><given-names>J.</given-names></string-name>, <string-name><surname>Garnett</surname><given-names>M.J.</given-names></string-name></person-group><article-title>GDSCTools for mining pharmacogenomic interactions in cancer</article-title>. <source>Bioinformatics</source>. <year>2018</year>; <volume>34</volume>:<fpage>1226</fpage>–<lpage>1228</lpage>.<pub-id pub-id-type="pmid">29186349</pub-id></mixed-citation>
    </ref>
    <ref id="B13">
      <label>13.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Feng</surname><given-names>F.</given-names></string-name>, <string-name><surname>Shen</surname><given-names>B.</given-names></string-name>, <string-name><surname>Mou</surname><given-names>X.</given-names></string-name>, <string-name><surname>Li</surname><given-names>Y.</given-names></string-name>, <string-name><surname>Li</surname><given-names>H.</given-names></string-name></person-group><article-title>Large-scale pharmacogenomic studies and drug response prediction for personalized cancer medicine</article-title>. <source>J. Genet. Genomics</source>. <year>2021</year>; <volume>48</volume>:<fpage>540</fpage>–<lpage>551</lpage>.<pub-id pub-id-type="pmid">34023295</pub-id></mixed-citation>
    </ref>
    <ref id="B14">
      <label>14.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Mansoori</surname><given-names>B.</given-names></string-name>, <string-name><surname>Mohammadi</surname><given-names>A.</given-names></string-name>, <string-name><surname>Davudian</surname><given-names>S.</given-names></string-name>, <string-name><surname>Shirjang</surname><given-names>S.</given-names></string-name>, <string-name><surname>Baradaran</surname><given-names>B.</given-names></string-name></person-group><article-title>The different mechanisms of cancer drug resistance: a brief review</article-title>. <source>Adv. Pharm. Bull.</source><year>2017</year>; <volume>7</volume>:<fpage>339</fpage>–<lpage>348</lpage>.<pub-id pub-id-type="pmid">29071215</pub-id></mixed-citation>
    </ref>
    <ref id="B15">
      <label>15.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Holohan</surname><given-names>C.</given-names></string-name>, <string-name><surname>Van Schaeybroeck</surname><given-names>S.</given-names></string-name>, <string-name><surname>Longley</surname><given-names>D.B.</given-names></string-name>, <string-name><surname>Johnston</surname><given-names>P.G.</given-names></string-name></person-group><article-title>Cancer drug resistance: an evolving paradigm</article-title>. <source>Nat. Rev. Cancer</source>. <year>2013</year>; <volume>13</volume>:<fpage>714</fpage>–<lpage>726</lpage>.<pub-id pub-id-type="pmid">24060863</pub-id></mixed-citation>
    </ref>
    <ref id="B16">
      <label>16.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Sharifi-Noghabi</surname><given-names>H.</given-names></string-name>, <string-name><surname>Jahangiri-Tazehkand</surname><given-names>S.</given-names></string-name>, <string-name><surname>Smirnov</surname><given-names>P.</given-names></string-name>, <string-name><surname>Hon</surname><given-names>C.</given-names></string-name>, <string-name><surname>Mammoliti</surname><given-names>A.</given-names></string-name>, <string-name><surname>Nair</surname><given-names>S.K.</given-names></string-name>, <string-name><surname>Mer</surname><given-names>A.S.</given-names></string-name>, <string-name><surname>Ester</surname><given-names>M.</given-names></string-name>, <string-name><surname>Haibe-Kains</surname><given-names>B.</given-names></string-name></person-group><article-title>Drug sensitivity prediction from cell line-based pharmacogenomics data: guidelines for developing machine learning models</article-title>. <source>Brief. Bioinform.</source><year>2021</year>; <volume>22</volume>:<fpage>bbab294</fpage>.<pub-id pub-id-type="pmid">34382071</pub-id></mixed-citation>
    </ref>
    <ref id="B17">
      <label>17.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Sakellaropoulos</surname><given-names>T.</given-names></string-name>, <string-name><surname>Vougas</surname><given-names>K.</given-names></string-name>, <string-name><surname>Narang</surname><given-names>S.</given-names></string-name>, <string-name><surname>Koinis</surname><given-names>F.</given-names></string-name>, <string-name><surname>Kotsinas</surname><given-names>A.</given-names></string-name>, <string-name><surname>Polyzos</surname><given-names>A.</given-names></string-name>, <string-name><surname>Moss</surname><given-names>T.J.</given-names></string-name>, <string-name><surname>Piha-Paul</surname><given-names>S.</given-names></string-name>, <string-name><surname>Zhou</surname><given-names>H.</given-names></string-name>, <string-name><surname>Kardala</surname><given-names>E.</given-names></string-name><etal>et al</etal>.</person-group><article-title>A deep learning framework for predicting response to therapy in cancer</article-title>. <source>Cell Rep.</source><year>2019</year>; <volume>29</volume>:<fpage>3367</fpage>–<lpage>3373</lpage>.<pub-id pub-id-type="pmid">31825821</pub-id></mixed-citation>
    </ref>
    <ref id="B18">
      <label>18.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Chiu</surname><given-names>Y.-C.</given-names></string-name>, <string-name><surname>Chen</surname><given-names>H.-I.H.</given-names></string-name>, <string-name><surname>Gorthi</surname><given-names>A.</given-names></string-name>, <string-name><surname>Mostavi</surname><given-names>M.</given-names></string-name>, <string-name><surname>Zheng</surname><given-names>S.</given-names></string-name>, <string-name><surname>Huang</surname><given-names>Y.</given-names></string-name>, <string-name><surname>Chen</surname><given-names>Y.</given-names></string-name></person-group><article-title>Deep learning of pharmacogenomics resources: moving towards precision oncology</article-title>. <source>Brief. Bioinform.</source><year>2020</year>; <volume>21</volume>:<fpage>2066</fpage>–<lpage>2083</lpage>.<pub-id pub-id-type="pmid">31813953</pub-id></mixed-citation>
    </ref>
    <ref id="B19">
      <label>19.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Adam</surname><given-names>G.</given-names></string-name>, <string-name><surname>Rampášek</surname><given-names>L.</given-names></string-name>, <string-name><surname>Safikhani</surname><given-names>Z.</given-names></string-name>, <string-name><surname>Smirnov</surname><given-names>P.</given-names></string-name>, <string-name><surname>Haibe-Kains</surname><given-names>B.</given-names></string-name>, <string-name><surname>Goldenberg</surname><given-names>A.</given-names></string-name></person-group><article-title>Machine learning approaches to drug response prediction: challenges and recent progress</article-title>. <source>NPJ Precis Oncol.</source><year>2020</year>; <volume>4</volume>:<fpage>19</fpage>.<pub-id pub-id-type="pmid">32566759</pub-id></mixed-citation>
    </ref>
    <ref id="B20">
      <label>20.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Bhinder</surname><given-names>B.</given-names></string-name>, <string-name><surname>Gilvary</surname><given-names>C.</given-names></string-name>, <string-name><surname>Madhukar</surname><given-names>N.S.</given-names></string-name>, <string-name><surname>Elemento</surname><given-names>O.</given-names></string-name></person-group><article-title>Artificial intelligence in cancer research and precision medicine</article-title>. <source>Cancer Discov.</source><year>2021</year>; <volume>11</volume>:<fpage>900</fpage>–<lpage>915</lpage>.<pub-id pub-id-type="pmid">33811123</pub-id></mixed-citation>
    </ref>
    <ref id="B21">
      <label>21.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Webber</surname><given-names>J.T.</given-names></string-name>, <string-name><surname>Kaushik</surname><given-names>S.</given-names></string-name>, <string-name><surname>Bandyopadhyay</surname><given-names>S.</given-names></string-name></person-group><article-title>Integration of tumor genomic data with cell lines using Multi-dimensional network modules improves cancer pharmacogenomics</article-title>. <source>Cell Syst.</source><year>2018</year>; <volume>7</volume>:<fpage>526</fpage>–<lpage>536</lpage>.<pub-id pub-id-type="pmid">30414925</pub-id></mixed-citation>
    </ref>
    <ref id="B22">
      <label>22.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Gerdes</surname><given-names>H.</given-names></string-name>, <string-name><surname>Casado</surname><given-names>P.</given-names></string-name>, <string-name><surname>Dokal</surname><given-names>A.</given-names></string-name>, <string-name><surname>Hijazi</surname><given-names>M.</given-names></string-name>, <string-name><surname>Akhtar</surname><given-names>N.</given-names></string-name>, <string-name><surname>Osuntola</surname><given-names>R.</given-names></string-name>, <string-name><surname>Rajeeve</surname><given-names>V.</given-names></string-name>, <string-name><surname>Fitzgibbon</surname><given-names>J.</given-names></string-name>, <string-name><surname>Travers</surname><given-names>J.</given-names></string-name>, <string-name><surname>Britton</surname><given-names>D.</given-names></string-name><etal>et al</etal>.</person-group><article-title>Drug ranking using machine learning systematically predicts the efficacy of anti-cancer drugs</article-title>. <source>Nat. Commun.</source><year>2021</year>; <volume>12</volume>:<fpage>1850</fpage>.<pub-id pub-id-type="pmid">33767176</pub-id></mixed-citation>
    </ref>
    <ref id="B23">
      <label>23.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Güvenç Paltun</surname><given-names>B.</given-names></string-name>, <string-name><surname>Mamitsuka</surname><given-names>H.</given-names></string-name>, <string-name><surname>Kaski</surname><given-names>S.</given-names></string-name></person-group><article-title>Improving drug response prediction by integrating multiple data sources: matrix factorization, kernel and network-based approaches</article-title>. <source>Brief. Bioinform.</source><year>2021</year>; <volume>22</volume>:<fpage>346</fpage>–<lpage>359</lpage>.<pub-id pub-id-type="pmid">31838491</pub-id></mixed-citation>
    </ref>
    <ref id="B24">
      <label>24.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Kuenzi</surname><given-names>B.M.</given-names></string-name>, <string-name><surname>Park</surname><given-names>J.</given-names></string-name>, <string-name><surname>Fong</surname><given-names>S.H.</given-names></string-name>, <string-name><surname>Sanchez</surname><given-names>K.S.</given-names></string-name>, <string-name><surname>Lee</surname><given-names>J.</given-names></string-name>, <string-name><surname>Kreisberg</surname><given-names>J.F.</given-names></string-name>, <string-name><surname>Ma</surname><given-names>J.</given-names></string-name>, <string-name><surname>Ideker</surname><given-names>T.</given-names></string-name></person-group><article-title>Predicting drug response and synergy using a deep learning model of human cancer cells</article-title>. <source>Cancer Cell</source>. <year>2020</year>; <volume>38</volume>:<fpage>672</fpage>–<lpage>684</lpage>.<pub-id pub-id-type="pmid">33096023</pub-id></mixed-citation>
    </ref>
    <ref id="B25">
      <label>25.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Peres da Silva</surname><given-names>R.</given-names></string-name>, <string-name><surname>Suphavilai</surname><given-names>C.</given-names></string-name>, <string-name><surname>Nagarajan</surname><given-names>N.</given-names></string-name></person-group><article-title>TUGDA: task uncertainty guided domain adaptation for robust generalization of cancer drug response prediction from in vitro to in vivo settings</article-title>. <source>Bioinformatics</source>. <year>2021</year>; <volume>37</volume>:<fpage>i76</fpage>–<lpage>i83</lpage>.<pub-id pub-id-type="pmid">34000002</pub-id></mixed-citation>
    </ref>
    <ref id="B26">
      <label>26.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Sharifi-Noghabi</surname><given-names>H.</given-names></string-name>, <string-name><surname>Peng</surname><given-names>S.</given-names></string-name>, <string-name><surname>Zolotareva</surname><given-names>O.</given-names></string-name>, <string-name><surname>Collins</surname><given-names>C.C.</given-names></string-name>, <string-name><surname>Ester</surname><given-names>M.</given-names></string-name></person-group><article-title>AITL: adversarial inductive transfer learning with input and output space adaptation for pharmacogenomics</article-title>. <source>Bioinformatics</source>. <year>2020</year>; <volume>36</volume>:<fpage>i380</fpage>–<lpage>i388</lpage>.<pub-id pub-id-type="pmid">32657371</pub-id></mixed-citation>
    </ref>
    <ref id="B27">
      <label>27.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Mourragui</surname><given-names>S.</given-names></string-name>, <string-name><surname>Loog</surname><given-names>M.</given-names></string-name>, <string-name><surname>Vis</surname><given-names>D.J.</given-names></string-name>, <string-name><surname>Moore</surname><given-names>K.</given-names></string-name>, <string-name><surname>Manjon</surname><given-names>A.G.</given-names></string-name>, <string-name><surname>van de Wiel</surname><given-names>M.A.</given-names></string-name>, <string-name><surname>Reinders</surname><given-names>M.J.T.</given-names></string-name>, <string-name><surname>Wessels</surname><given-names>L.F.A.</given-names></string-name></person-group><article-title>Predicting patient response with models trained on cell lines and patient-derived xenografts by nonlinear transfer learning</article-title>. <source>PNAS</source>. <year>2021</year>; <volume>118</volume>:<fpage>e2106682118</fpage>.<pub-id pub-id-type="pmid">34873056</pub-id></mixed-citation>
    </ref>
    <ref id="B28">
      <label>28.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Nguyen</surname><given-names>T.</given-names></string-name>, <string-name><surname>Nguyen</surname><given-names>G.T.T.</given-names></string-name>, <string-name><surname>Nguyen</surname><given-names>T.</given-names></string-name>, <string-name><surname>Le</surname><given-names>D.-H.</given-names></string-name></person-group><article-title>Graph convolutional networks for drug response prediction</article-title>. <source>IEEE/ACM Trans. Comput. Biol. Bioinform.</source><year>2022</year>; <volume>19</volume>:<fpage>146</fpage>–<lpage>154</lpage>.<pub-id pub-id-type="pmid">33606633</pub-id></mixed-citation>
    </ref>
    <ref id="B29">
      <label>29.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Liu</surname><given-names>X.</given-names></string-name>, <string-name><surname>Song</surname><given-names>C.</given-names></string-name>, <string-name><surname>Huang</surname><given-names>F.</given-names></string-name>, <string-name><surname>Fu</surname><given-names>H.</given-names></string-name>, <string-name><surname>Xiao</surname><given-names>W.</given-names></string-name>, <string-name><surname>Zhang</surname><given-names>W.</given-names></string-name></person-group><article-title>GraphCDR: a graph neural network method with contrastive learning for cancer drug response prediction</article-title>. <source>Brief. Bioinform.</source><year>2022</year>; <volume>23</volume>:<fpage>bbab457</fpage>.<pub-id pub-id-type="pmid">34727569</pub-id></mixed-citation>
    </ref>
    <ref id="B30">
      <label>30.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Liu</surname><given-names>Q.</given-names></string-name>, <string-name><surname>Hu</surname><given-names>Z.</given-names></string-name>, <string-name><surname>Jiang</surname><given-names>R.</given-names></string-name>, <string-name><surname>Zhou</surname><given-names>M.</given-names></string-name></person-group><article-title>DeepCDR: a hybrid graph convolutional network for predicting cancer drug response</article-title>. <source>Bioinformatics</source>. <year>2020</year>; <volume>36</volume>:<fpage>i911</fpage>–<lpage>i918</lpage>.<pub-id pub-id-type="pmid">33381841</pub-id></mixed-citation>
    </ref>
    <ref id="B31">
      <label>31.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Haibe-Kains</surname><given-names>B.</given-names></string-name>, <string-name><surname>El-Hachem</surname><given-names>N.</given-names></string-name>, <string-name><surname>Birkbak</surname><given-names>N.J.</given-names></string-name>, <string-name><surname>Jin</surname><given-names>A.C.</given-names></string-name>, <string-name><surname>Beck</surname><given-names>A.H.</given-names></string-name>, <string-name><surname>Aerts</surname><given-names>H.J.W.L.</given-names></string-name>, <string-name><surname>Quackenbush</surname><given-names>J.</given-names></string-name></person-group><article-title>Inconsistency in large pharmacogenomic studies</article-title>. <source>Nature</source>. <year>2013</year>; <volume>504</volume>:<fpage>389</fpage>–<lpage>393</lpage>.<pub-id pub-id-type="pmid">24284626</pub-id></mixed-citation>
    </ref>
    <ref id="B32">
      <label>32.</label>
      <mixed-citation publication-type="journal"><collab>Cancer cell line encyclopedia consortium and genomics of drug sensitivity in cancer consortium</collab><article-title>Pharmacogenomic agreement between two cancer cell line data sets</article-title>. <source>Nature</source>. <year>2015</year>; <volume>528</volume>:<fpage>84</fpage>–<lpage>87</lpage>.<pub-id pub-id-type="pmid">26570998</pub-id></mixed-citation>
    </ref>
    <ref id="B33">
      <label>33.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Safikhani</surname><given-names>Z.</given-names></string-name>, <string-name><surname>El-Hachem</surname><given-names>N.</given-names></string-name>, <string-name><surname>Quevedo</surname><given-names>R.</given-names></string-name>, <string-name><surname>Smirnov</surname><given-names>P.</given-names></string-name>, <string-name><surname>Goldenberg</surname><given-names>A.</given-names></string-name>, <string-name><surname>Juul Birkbak</surname><given-names>N.</given-names></string-name>, <string-name><surname>Mason</surname><given-names>C.</given-names></string-name>, <string-name><surname>Hatzis</surname><given-names>C.</given-names></string-name>, <string-name><surname>Shi</surname><given-names>L.</given-names></string-name>, <string-name><surname>Aerts</surname><given-names>H.J.</given-names></string-name><etal>et al</etal>.</person-group><article-title>Assessment of pharmacogenomic agreement</article-title>. <source>F1000Res.</source><year>2016</year>; <volume>5</volume>:<fpage>825</fpage>.<pub-id pub-id-type="pmid">27408686</pub-id></mixed-citation>
    </ref>
    <ref id="B34">
      <label>34.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Bouhaddou</surname><given-names>M.</given-names></string-name>, <string-name><surname>DiStefano</surname><given-names>M.S.</given-names></string-name>, <string-name><surname>Riesel</surname><given-names>E.A.</given-names></string-name>, <string-name><surname>Carrasco</surname><given-names>E.</given-names></string-name>, <string-name><surname>Holzapfel</surname><given-names>H.Y.</given-names></string-name>, <string-name><surname>Jones</surname><given-names>D.C.</given-names></string-name>, <string-name><surname>Smith</surname><given-names>G.R.</given-names></string-name>, <string-name><surname>Stern</surname><given-names>A.D.</given-names></string-name>, <string-name><surname>Somani</surname><given-names>S.S.</given-names></string-name>, <string-name><surname>Thompson</surname><given-names>T.V.</given-names></string-name><etal>et al</etal>.</person-group><article-title>Drug response consistency in CCLE and CGP</article-title>. <source>Nature</source>. <year>2016</year>; <volume>540</volume>:<fpage>E9</fpage>–<lpage>E10</lpage>.<pub-id pub-id-type="pmid">27905419</pub-id></mixed-citation>
    </ref>
    <ref id="B35">
      <label>35.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Haverty</surname><given-names>P.M.</given-names></string-name>, <string-name><surname>Lin</surname><given-names>E.</given-names></string-name>, <string-name><surname>Tan</surname><given-names>J.</given-names></string-name>, <string-name><surname>Yu</surname><given-names>Y.</given-names></string-name>, <string-name><surname>Lam</surname><given-names>B.</given-names></string-name>, <string-name><surname>Lianoglou</surname><given-names>S.</given-names></string-name>, <string-name><surname>Neve</surname><given-names>R.M.</given-names></string-name>, <string-name><surname>Martin</surname><given-names>S.</given-names></string-name>, <string-name><surname>Settleman</surname><given-names>J.</given-names></string-name>, <string-name><surname>Yauch</surname><given-names>R.L.</given-names></string-name><etal>et al</etal>.</person-group><article-title>Reproducible pharmacogenomic profiling of cancer cell line panels</article-title>. <source>Nature</source>. <year>2016</year>; <volume>533</volume>:<fpage>333</fpage>–<lpage>337</lpage>.<pub-id pub-id-type="pmid">27193678</pub-id></mixed-citation>
    </ref>
    <ref id="B36">
      <label>36.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Safikhani</surname><given-names>Z.</given-names></string-name>, <string-name><surname>Smirnov</surname><given-names>P.</given-names></string-name>, <string-name><surname>Freeman</surname><given-names>M.</given-names></string-name>, <string-name><surname>El-Hachem</surname><given-names>N.</given-names></string-name>, <string-name><surname>She</surname><given-names>A.</given-names></string-name>, <string-name><surname>Rene</surname><given-names>Q.</given-names></string-name>, <string-name><surname>Goldenberg</surname><given-names>A.</given-names></string-name>, <string-name><surname>Birkbak</surname><given-names>N.J.</given-names></string-name>, <string-name><surname>Hatzis</surname><given-names>C.</given-names></string-name>, <string-name><surname>Shi</surname><given-names>L.</given-names></string-name><etal>et al</etal>.</person-group><article-title>Revisiting inconsistency in large pharmacogenomic studies</article-title>. <source>F1000Res.</source><year>2016</year>; <volume>5</volume>:<fpage>2333</fpage>.<pub-id pub-id-type="pmid">28928933</pub-id></mixed-citation>
    </ref>
    <ref id="B37">
      <label>37.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Pozdeyev</surname><given-names>N.</given-names></string-name>, <string-name><surname>Yoo</surname><given-names>M.</given-names></string-name>, <string-name><surname>Mackie</surname><given-names>R.</given-names></string-name>, <string-name><surname>Schweppe</surname><given-names>R.E.</given-names></string-name>, <string-name><surname>Tan</surname><given-names>A.C.</given-names></string-name>, <string-name><surname>Haugen</surname><given-names>B.R.</given-names></string-name></person-group><article-title>Integrating heterogeneous drug sensitivity data from cancer pharmacogenomic studies</article-title>. <source>Oncotarget</source>. <year>2016</year>; <volume>7</volume>:<fpage>51619</fpage>–<lpage>51625</lpage>.<pub-id pub-id-type="pmid">27322211</pub-id></mixed-citation>
    </ref>
    <ref id="B38">
      <label>38.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Ben-David</surname><given-names>U.</given-names></string-name>, <string-name><surname>Siranosian</surname><given-names>B.</given-names></string-name>, <string-name><surname>Ha</surname><given-names>G.</given-names></string-name>, <string-name><surname>Tang</surname><given-names>H.</given-names></string-name>, <string-name><surname>Oren</surname><given-names>Y.</given-names></string-name>, <string-name><surname>Hinohara</surname><given-names>K.</given-names></string-name>, <string-name><surname>Strathdee</surname><given-names>C.A.</given-names></string-name>, <string-name><surname>Dempster</surname><given-names>J.</given-names></string-name>, <string-name><surname>Lyons</surname><given-names>N.J.</given-names></string-name>, <string-name><surname>Burns</surname><given-names>R.</given-names></string-name><etal>et al</etal>.</person-group><article-title>Genetic and transcriptional evolution alters cancer cell line drug response</article-title>. <source>Nature</source>. <year>2018</year>; <volume>560</volume>:<fpage>325</fpage>–<lpage>330</lpage>.<pub-id pub-id-type="pmid">30089904</pub-id></mixed-citation>
    </ref>
    <ref id="B39">
      <label>39.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Feizi</surname><given-names>N.</given-names></string-name>, <string-name><surname>Nair</surname><given-names>S.K.</given-names></string-name>, <string-name><surname>Smirnov</surname><given-names>P.</given-names></string-name>, <string-name><surname>Beri</surname><given-names>G.</given-names></string-name>, <string-name><surname>Eeles</surname><given-names>C.</given-names></string-name>, <string-name><surname>Esfahani</surname><given-names>P.N.</given-names></string-name>, <string-name><surname>Nakano</surname><given-names>M.</given-names></string-name>, <string-name><surname>Tkachuk</surname><given-names>D.</given-names></string-name>, <string-name><surname>Mammoliti</surname><given-names>A.</given-names></string-name>, <string-name><surname>Gorobets</surname><given-names>E.</given-names></string-name><etal>et al</etal>.</person-group><article-title>PharmacoDB 2.0: improving scalability and transparency of in vitro pharmacogenomics analysis</article-title>. <source>Nucleic Acids Res.</source><year>2022</year>; <volume>50</volume>:<fpage>D1348</fpage>–<lpage>D1357</lpage>.<pub-id pub-id-type="pmid">34850112</pub-id></mixed-citation>
    </ref>
    <ref id="B40">
      <label>40.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Luna</surname><given-names>A.</given-names></string-name>, <string-name><surname>Elloumi</surname><given-names>F.</given-names></string-name>, <string-name><surname>Varma</surname><given-names>S.</given-names></string-name>, <string-name><surname>Wang</surname><given-names>Y.</given-names></string-name>, <string-name><surname>Rajapakse</surname><given-names>V.N.</given-names></string-name>, <string-name><surname>Aladjem</surname><given-names>M.I.</given-names></string-name>, <string-name><surname>Robert</surname><given-names>J.</given-names></string-name>, <string-name><surname>Sander</surname><given-names>C.</given-names></string-name>, <string-name><surname>Pommier</surname><given-names>Y.</given-names></string-name>, <string-name><surname>Reinhold</surname><given-names>W.C.</given-names></string-name></person-group><article-title>CellMiner cross-database (CellMinerCDB) version 1.2: exploration of patient-derived cancer cell line pharmacogenomics</article-title>. <source>Nucleic Acids Res.</source><year>2021</year>; <volume>49</volume>:<fpage>D1083</fpage>–<lpage>D1093</lpage>.<pub-id pub-id-type="pmid">33196823</pub-id></mixed-citation>
    </ref>
    <ref id="B41">
      <label>41.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Rees</surname><given-names>M.G.</given-names></string-name>, <string-name><surname>Seashore-Ludlow</surname><given-names>B.</given-names></string-name>, <string-name><surname>Cheah</surname><given-names>J.H.</given-names></string-name>, <string-name><surname>Adams</surname><given-names>D.J.</given-names></string-name>, <string-name><surname>Price</surname><given-names>E.V.</given-names></string-name>, <string-name><surname>Gill</surname><given-names>S.</given-names></string-name>, <string-name><surname>Javaid</surname><given-names>S.</given-names></string-name>, <string-name><surname>Coletti</surname><given-names>M.E.</given-names></string-name>, <string-name><surname>Jones</surname><given-names>V.L.</given-names></string-name>, <string-name><surname>Bodycombe</surname><given-names>N.E.</given-names></string-name><etal>et al</etal>.</person-group><article-title>Correlating chemical sensitivity and basal gene expression reveals mechanism of action</article-title>. <source>Nat. Chem. Biol.</source><year>2016</year>; <volume>12</volume>:<fpage>109</fpage>–<lpage>116</lpage>.<pub-id pub-id-type="pmid">26656090</pub-id></mixed-citation>
    </ref>
    <ref id="B42">
      <label>42.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>van der Meer</surname><given-names>D.</given-names></string-name>, <string-name><surname>Barthorpe</surname><given-names>S.</given-names></string-name>, <string-name><surname>Yang</surname><given-names>W.</given-names></string-name>, <string-name><surname>Lightfoot</surname><given-names>H.</given-names></string-name>, <string-name><surname>Hall</surname><given-names>C.</given-names></string-name>, <string-name><surname>Gilbert</surname><given-names>J.</given-names></string-name>, <string-name><surname>Francies</surname><given-names>H.E.</given-names></string-name>, <string-name><surname>Garnett</surname><given-names>M.J.</given-names></string-name></person-group><article-title>Cell model Passports—a hub for clinical, genetic and functional datasets of preclinical cancer models</article-title>. <source>Nucleic Acids Res.</source><year>2018</year>; <volume>47</volume>:<fpage>D923</fpage>–<lpage>D929</lpage>.</mixed-citation>
    </ref>
    <ref id="B43">
      <label>43.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Bairoch</surname><given-names>A.</given-names></string-name></person-group><article-title>The cellosaurus, a cell-line knowledge resource</article-title>. <source>J. Biomol. Tech.</source><year>2018</year>; <volume>29</volume>:<fpage>25</fpage>–<lpage>38</lpage>.<pub-id pub-id-type="pmid">29805321</pub-id></mixed-citation>
    </ref>
    <ref id="B44">
      <label>44.</label>
      <mixed-citation publication-type="other"><person-group person-group-type="author"><string-name><surname>Plummer</surname><given-names>M.</given-names></string-name></person-group><article-title>Why JAGS? Extending JAGS differences between JAGS and BUGS rjags conclusions JAGS: just another gibbs sampler</article-title>. <year>2007</year>; <uri xlink:href="https://pdfs.semanticscholar.org/837b/9203abc8b3416e620d4c99d8500b4bd9be20.pdf">https://pdfs.semanticscholar.org/837b/9203abc8b3416e620d4c99d8500b4bd9be20.pdf</uri>.</mixed-citation>
    </ref>
    <ref id="B45">
      <label>45.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Kumar</surname><given-names>R.</given-names></string-name>, <string-name><surname>Carroll</surname><given-names>C.</given-names></string-name>, <string-name><surname>Hartikainen</surname><given-names>A.</given-names></string-name>, <string-name><surname>Martin</surname><given-names>O.</given-names></string-name></person-group><article-title>ArviZ a unified library for exploratory analysis of bayesian models in python</article-title>. <source>J. Open Source Softw.</source><year>2019</year>; <volume>4</volume>:<fpage>1143</fpage>.</mixed-citation>
    </ref>
    <ref id="B46">
      <label>46.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Zehir</surname><given-names>A.</given-names></string-name>, <string-name><surname>Benayed</surname><given-names>R.</given-names></string-name>, <string-name><surname>Shah</surname><given-names>R.H.</given-names></string-name>, <string-name><surname>Syed</surname><given-names>A.</given-names></string-name>, <string-name><surname>Middha</surname><given-names>S.</given-names></string-name>, <string-name><surname>Kim</surname><given-names>H.R.</given-names></string-name>, <string-name><surname>Srinivasan</surname><given-names>P.</given-names></string-name>, <string-name><surname>Gao</surname><given-names>J.</given-names></string-name>, <string-name><surname>Chakravarty</surname><given-names>D.</given-names></string-name>, <string-name><surname>Devlin</surname><given-names>S.M.</given-names></string-name><etal>et al</etal>.</person-group><article-title>Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients</article-title>. <source>Nat. Med.</source><year>2017</year>; <volume>23</volume>:<fpage>703</fpage>–<lpage>713</lpage>.<pub-id pub-id-type="pmid">28481359</pub-id></mixed-citation>
    </ref>
    <ref id="B47">
      <label>47.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Stockley</surname><given-names>T.L.</given-names></string-name>, <string-name><surname>Oza</surname><given-names>A.M.</given-names></string-name>, <string-name><surname>Berman</surname><given-names>H.K.</given-names></string-name>, <string-name><surname>Leighl</surname><given-names>N.B.</given-names></string-name>, <string-name><surname>Knox</surname><given-names>J.J.</given-names></string-name>, <string-name><surname>Shepherd</surname><given-names>F.A.</given-names></string-name>, <string-name><surname>Chen</surname><given-names>E.X.</given-names></string-name>, <string-name><surname>Krzyzanowska</surname><given-names>M.K.</given-names></string-name>, <string-name><surname>Dhani</surname><given-names>N.</given-names></string-name>, <string-name><surname>Joshua</surname><given-names>A.M.</given-names></string-name><etal>et al</etal>.</person-group><article-title>Molecular profiling of advanced solid tumors and patient outcomes with genotype-matched clinical trials: the princess margaret IMPACT/COMPACT trial</article-title>. <source>Genome Med.</source><year>2016</year>; <volume>8</volume>:<fpage>109</fpage>.<pub-id pub-id-type="pmid">27782854</pub-id></mixed-citation>
    </ref>
    <ref id="B48">
      <label>48.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Boehm</surname><given-names>J.S.</given-names></string-name>, <string-name><surname>Garnett</surname><given-names>M.J.</given-names></string-name>, <string-name><surname>Adams</surname><given-names>D.J.</given-names></string-name>, <string-name><surname>Francies</surname><given-names>H.E.</given-names></string-name>, <string-name><surname>Golub</surname><given-names>T.R.</given-names></string-name>, <string-name><surname>Hahn</surname><given-names>W.C.</given-names></string-name>, <string-name><surname>Iorio</surname><given-names>F.</given-names></string-name>, <string-name><surname>McFarland</surname><given-names>J.M.</given-names></string-name>, <string-name><surname>Parts</surname><given-names>L.</given-names></string-name>, <string-name><surname>Vazquez</surname><given-names>F.</given-names></string-name></person-group><article-title>Cancer research needs a better map</article-title>. <source>Nature</source>. <year>2021</year>; <volume>589</volume>:<fpage>514</fpage>–<lpage>516</lpage>.<pub-id pub-id-type="pmid">33500573</pub-id></mixed-citation>
    </ref>
    <ref id="B49">
      <label>49.</label>
      <mixed-citation publication-type="other"><person-group person-group-type="author"><string-name><surname>Badria</surname><given-names>F.A.</given-names></string-name></person-group><article-title>Drug repurposing: hypothesis, molecular aspects and therapeutic applications BoD – books on demand</article-title>. <year>2020</year>; <uri xlink:href="https://www.intechopen.com/books/9086">https://www.intechopen.com/books/9086</uri>.</mixed-citation>
    </ref>
    <ref id="B50">
      <label>50.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Wu</surname><given-names>Z.</given-names></string-name>, <string-name><surname>Lawrence</surname><given-names>P.J.</given-names></string-name>, <string-name><surname>Ma</surname><given-names>A.</given-names></string-name>, <string-name><surname>Zhu</surname><given-names>J.</given-names></string-name>, <string-name><surname>Xu</surname><given-names>D.</given-names></string-name>, <string-name><surname>Ma</surname><given-names>Q.</given-names></string-name></person-group><article-title>Single-Cell techniques and deep learning in predicting drug response</article-title>. <source>Trends Pharmacol. Sci.</source><year>2020</year>; <volume>41</volume>:<fpage>1050</fpage>–<lpage>1065</lpage>.<pub-id pub-id-type="pmid">33153777</pub-id></mixed-citation>
    </ref>
    <ref id="B51">
      <label>51.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Suphavilai</surname><given-names>C.</given-names></string-name>, <string-name><surname>Chia</surname><given-names>S.</given-names></string-name>, <string-name><surname>Sharma</surname><given-names>A.</given-names></string-name>, <string-name><surname>Tu</surname><given-names>L.</given-names></string-name>, <string-name><surname>Da Silva</surname><given-names>R.P.</given-names></string-name>, <string-name><surname>Mongia</surname><given-names>A.</given-names></string-name>, <string-name><surname>DasGupta</surname><given-names>R.</given-names></string-name>, <string-name><surname>Nagarajan</surname><given-names>N.</given-names></string-name></person-group><article-title>Predicting heterogeneity in clone-specific therapeutic vulnerabilities using single-cell transcriptomic signatures</article-title>. <source>Genome Medicine</source>. <year>2021</year>; <volume>13</volume>:<fpage>189</fpage>.<pub-id pub-id-type="pmid">34915921</pub-id></mixed-citation>
    </ref>
    <ref id="B52">
      <label>52.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Keshava</surname><given-names>N.</given-names></string-name>, <string-name><surname>Toh</surname><given-names>T.S.</given-names></string-name>, <string-name><surname>Yuan</surname><given-names>H.</given-names></string-name>, <string-name><surname>Yang</surname><given-names>B.</given-names></string-name>, <string-name><surname>Menden</surname><given-names>M.P.</given-names></string-name>, <string-name><surname>Wang</surname><given-names>D</given-names></string-name></person-group><article-title>Defining subpopulations of differential drug response to reveal novel target populations</article-title>. <source>NPJ Syst. Biol. Appl.</source><year>2019</year>; <volume>5</volume>:<fpage>36</fpage>.<pub-id pub-id-type="pmid">31602313</pub-id></mixed-citation>
    </ref>
  </ref-list>
</back>
